{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:42Z","timestamp":1791219402124,"version":"4.1.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Olle Engvist Foundation"},{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health","award":["T32AR007080-44S1"],"award-info":[{"award-number":["T32AR007080-44S1"]}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ceruvia Lifesciences"},{"DOI":"10.13039\/100019759","name":"Wallace Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019759","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clusterbusters, Inc"},{"name":"VA R&D"},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019759","name":"Wallace Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019759","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA R&D"},{"name":"Vikram Sodhi Endowed Chair of Psychiatry"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic psychedelic studies, propose criteria for suitable active placebos, and review interventions that may putatively fit these criteria. Considerations for the characteristics of ideal active placebos in classic psychedelic studies include (1) acute psychoactive effects, (2) acute physiological effects, (3) onset and duration of acute effects, (4) safety, and (5) lack of therapeutic effects in the target disease. We identified several pharmacological agents that may have potential as active placebos in trials involving moderate-to-high doses of certain short-acting and long-acting classic psychedelics, as well as low-dose administration and microdosing regimes. To accurately assess the safety and efficacy of classic psychedelics as therapeutics, future research should apply a thoughtful process for selecting active placebos and consider ancillary strategies to improve blinding in trials involving these substances.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaf023","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:49:51Z","timestamp":1743792591000},"source":"Crossref","is-referenced-by-count":29,"title":["Addressing blinding in classic psychedelic studies with innovative active placebos"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-8530","authenticated-orcid":false,"given":"Jacob S","family":"Aday","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of Michigan , Ann Arbor, MI ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-7566","authenticated-orcid":false,"given":"Otto","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Karolinska Institute ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle A D","family":"Schindler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT ,","place":["United States"]},{"name":"Neurology Service, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Cyril","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine , New Haven, CT ,","place":["United States"]},{"name":"Neuropsychiatry Firm, VA Connecticut Healthcare System , West Haven, CT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"2025042903412323400_CIT0001","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bpsc.2024.01.007","article-title":"Serotonergic psychedelics: a comparative review of efficacy, safety, pharmacokinetics, and binding profile","volume":"9","author":"Holze","year":"2024","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging."},{"key":"2025042903412323400_CIT0002","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","article-title":"Phenomenology, structure, and dynamic of psychedelic states","volume-title":"Behavioral Neurobiology of Psychedelic Drugs","author":"Preller","year":"2018"},{"key":"2025042903412323400_CIT0003","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"2025042903412323400_CIT0004","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache."},{"key":"2025042903412323400_CIT0005","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA."},{"key":"2025042903412323400_CIT0006","doi-asserted-by":"publisher","first-page":"122993","DOI":"10.1016\/j.jns.2024.122993","article-title":"Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial","volume":"460","author":"Schindler","year":"2024","journal-title":"J Neurol Sci."},{"key":"2025042903412323400_CIT0007","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0008","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00213-024-06620-x","article-title":"Psychedelic-assisted psychotherapy: where is the psychotherapy research","volume":"241","author":"Aday","year":"2024","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0009","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol (Oxf)."},{"key":"2025042903412323400_CIT0010","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry."},{"key":"2025042903412323400_CIT0011","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","article-title":"The placebo effect in pain therapies","volume":"59","author":"Colloca","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"2025042903412323400_CIT0012","doi-asserted-by":"publisher","first-page":"03331024231218392","DOI":"10.1177\/03331024231218392","article-title":"Placebo and nocebo in the treatment of migraine: how much does real world effectiveness depend on contextual effects","volume":"43","author":"Basedau","year":"2023","journal-title":"Cephalalgia."},{"key":"2025042903412323400_CIT0013","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2024.0994","article-title":"Differential outcomes of placebo treatment across 9 psychiatric disorders: a systematic review and meta-analysis","volume":"81","author":"Bschor","year":"2024","journal-title":"JAMA Psychiatry."},{"key":"2025042903412323400_CIT0014","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"2025042903412323400_CIT0015","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/revneuro-2020-0094","article-title":"Psychedelic drugs and perception: a narrative review of the first era of research","volume":"32","author":"Aday","year":"2021","journal-title":"Rev Neurosci."},{"key":"2025042903412323400_CIT0016","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euroneuro.2023.09.007","article-title":"Methodological concerns in psychedelic research: the issues of nonequivalent psychological support and generalizability","volume":"78","author":"Zeifman","year":"2024","journal-title":"Eur Neuropsychopharmacol."},{"key":"2025042903412323400_CIT0017","doi-asserted-by":"publisher","first-page":"47000","DOI":"10.4088\/JCP.22r14518","article-title":"Control conditions in randomized trials of psychedelics: an ACTTION systematic review","volume":"84","author":"Nayak","year":"2023","journal-title":"J Clin Psychiatry."},{"key":"2025042903412323400_CIT0018","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/psymed.2023.0028","article-title":"A systematic review of study design and placebo controls in psychedelic research","volume":"2","author":"Wen","year":"2024","journal-title":"Psychedelic Med"},{"key":"2025042903412323400_CIT0019","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bpsc.2024.02.004","article-title":"Expectancy effects in psychedelic trials","volume":"9","author":"Szigeti","year":"2024","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2025042903412323400_CIT0020","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry."},{"key":"2025042903412323400_CIT0021","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jama.2024.13370","article-title":"Psychedelic therapy scrutinized by FDA advisory committee","volume":"332","author":"Marks","year":"2024","journal-title":"JAMA."},{"key":"2025042903412323400_CIT0022","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat Ment Health"},{"key":"2025042903412323400_CIT0023","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"2025042903412323400_CIT0024","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","article-title":"Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects","volume":"226","author":"MacLean","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0025","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","article-title":"Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the \u03ba opioid agonist salvinorin a in humans","volume":"72","author":"Ranganathan","year":"2012","journal-title":"Biol Psychiatry."},{"key":"2025042903412323400_CIT0026","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00213-022-06065-0","article-title":"Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT","volume":"239","author":"Barker","year":"2022","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0027","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/ph14020116","article-title":"Pharmacokinetics and pharmacodynamics of salvinorin A and Salvia divinorum: clinical and forensic aspects","volume":"14","author":"Brito-da-Costa","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)."},{"key":"2025042903412323400_CIT0028","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159x13666150727220944","article-title":"Kappa opioids, salvinorin A and major depressive disorder","volume":"14","author":"Taylor","year":"2016","journal-title":"Curr Neuropharmacol."},{"key":"2025042903412323400_CIT0029","doi-asserted-by":"publisher","first-page":"16392","DOI":"10.1038\/s41598-020-73216-8","article-title":"The acute effects of the atypical dissociative hallucinogen salvinorin A on functional connectivity in the human brain","volume":"10","author":"Doss","year":"2020","journal-title":"Sci Rep."},{"key":"2025042903412323400_CIT0030","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bjp.0700971","article-title":"The effects of spiradoline (U-62066E), a \u03ba-opioid receptor agonist, on neuroendocrine function in man","volume":"120","author":"Ur","year":"1997","journal-title":"Br J Pharmacol."},{"key":"2025042903412323400_CIT0031","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1196\/annals.1432.003","article-title":"Dextromethorphan","volume":"1139","author":"Banken","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"2025042903412323400_CIT0032","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0033","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2025042903412323400_CIT0034","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2025042903412323400_CIT0035","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-012-2680-6","article-title":"High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens","volume":"223","author":"Reissig","year":"2012","journal-title":"Psychopharmacology (Berl)."},{"key":"2025042903412323400_CIT0036","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/psymed.2023.0035","article-title":"Double-Blind comparison of the two hallucinogens dextromethorphan and psilocybin: experience-dependent and enduring psychological effects in healthy volunteers","volume":"1","author":"Mathai","year":"2023","journal-title":"Psychedelic Med"},{"key":"2025042903412323400_CIT0037","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-023-01032-5","article-title":"Dextromethorphan-Bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials","volume":"37","author":"Akbar","year":"2023","journal-title":"CNS Drugs."},{"key":"2025042903412323400_CIT0038","doi-asserted-by":"publisher","first-page":"609","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy","year":"2023","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"2025042903412323400_CIT0039","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol."},{"key":"2025042903412323400_CIT0040","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1080\/10826084.2022.2063893","article-title":"A systematic review of trends in US attitudes toward cannabis legalization","volume":"57","author":"Chiu","year":"2022","journal-title":"Subst Use Misuse."},{"key":"2025042903412323400_CIT0041","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/0269881121997099","article-title":"Cannabis-induced oceanic boundlessness","volume":"35","author":"Earleywine","year":"2021","journal-title":"J. Psychopharmacol. (Oxf)."},{"key":"2025042903412323400_CIT0042","doi-asserted-by":"publisher","first-page":"103357","DOI":"10.1016\/j.concog.2022.103357","article-title":"The altered state of consciousness induced by \u03949-THC","volume":"102","author":"Murray","year":"2022","journal-title":"Conscious Cogn."},{"key":"2025042903412323400_CIT0043","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"2025042903412323400_CIT0044","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41386-024-01809-2","article-title":"Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine","volume":"49","author":"Murray","year":"2024","journal-title":"Neuropsychopharmacology."},{"key":"2025042903412323400_CIT0045","doi-asserted-by":"publisher","first-page":"109166","DOI":"10.1016\/j.neuropharm.2022.109166","article-title":"Psychedelics as preventive treatment in headache and chronic pain disorders","volume":"215","author":"Schindler","year":"2022","journal-title":"Neuropharmacology."},{"key":"2025042903412323400_CIT0046","volume-title":"Psychedelic Outlaws: The Movement Revolutionizing Modern Medicine","author":"Kempner","year":"2024"},{"key":"2025042903412323400_CIT0047","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-02900-4","article-title":"LSD increases sleep duration the night after microdosing","volume":"14","author":"Allen","year":"2024","journal-title":"Transl Psychiatry."},{"key":"2025042903412323400_CIT0048","doi-asserted-by":"publisher","first-page":"104706","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci Biobehav Rev."},{"key":"2025042903412323400_CIT0049","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose\u2013response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict Biol."},{"key":"2025042903412323400_CIT0050","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol Psychiatry."},{"key":"2025042903412323400_CIT0051","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2023","journal-title":"Neuropsychopharmacology."},{"key":"2025042903412323400_CIT0052","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpainsymman.2011.03.026","article-title":"Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial","volume":"43","author":"Kerr","year":"2012","journal-title":"J Pain Symptom Manag."},{"key":"2025042903412323400_CIT0053","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1091399","article-title":"Case report: methylphenidate improved chronic pain in an adult patient with attention deficit hyperactivity disorder","volume":"14","author":"Zain","year":"2023","journal-title":"Front Psychiatry."},{"key":"2025042903412323400_CIT0054","doi-asserted-by":"publisher","first-page":"2045125320948356","DOI":"10.1177\/2045125320948356","article-title":"Psychedelics and virtual reality: parallels and applications","volume":"10","author":"Aday","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"2025042903412323400_CIT0055","doi-asserted-by":"publisher","first-page":"1198103","DOI":"10.3389\/fpsyt.2023.1198103","article-title":"Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study","volume":"14","author":"Kaup","year":"2023","journal-title":"Front Psychiatry."},{"key":"2025042903412323400_CIT0056","doi-asserted-by":"publisher","first-page":"e2945","DOI":"10.1002\/cpp.2945","article-title":"Therapeutic frameworks in integration sessions in substance-assisted psychotherapy: a systematised review","volume":"31","author":"Thal","year":"2024","journal-title":"Clin Psychol Psychother."},{"key":"2025042903412323400_CIT0057","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol (Oxf)."},{"key":"2025042903412323400_CIT0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front Psychiatry."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf023\/62870584\/pyaf023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/4\/pyaf023\/62870584\/pyaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/4\/pyaf023\/62870584\/pyaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:41:28Z","timestamp":1745912488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf023\/8106348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf023","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"pyaf023"}}